Bone Biologics Corp (BBLG) is a clinical-stage medical device company with no revenue and a single asset class of consequence: cash. At March 31, 2026, the company held $4.53 million in cash, substantially all ($4.1 million) in a flexible CD at Bank of America with no withdrawal penalty. Under a liquidation lens, this cash position is the entire recoverable asset base — the company carries no AR, no inventory, no PP&E, and no capitalized intangibles with liquidation value. The NELL-1/DBM license from UCLA TDG is a cost-center obligation, not an asset: it carries contingent milestone obligations totaling up to $1.75 million in future cash payments (Pivotal Study enrollment: $250,000; PMA approval: $500,000; first commercial sale: $1,000,000) plus an $8.0 million Diligence Fee triggered by first licensed product sale. The Diligence Fee obligation survives license termination and must be transferred with any asset sale — this is a structurally subordinated liability that attaches to the only piece of IP the company holds. Filing does not separately tag the Diligence Fee or UCLA milestone obligations in XBRL; they appear only in the Commitments and Contingencies footnote narrative. On the liability side, the balance sheet carries accounts payable and accrued expenses (magnitude not separately tagged in XBRL but referenced in cash flow as a $74,082 decrease in the quarter), a warrant liability of $438 (Level 3, de minimis), and no debt. Accumulated deficit stands at $88.9 million as of March 31, 2026. Operating cash burn was $804,282 for Q1 2026, implying a run rate of approximately $3.2 million annually against $4.53 million of cash. Management states cash will fund operations into Q4 2026 — consistent with roughly 5-6 months of runway from the filing date. No financing occurred in Q1 2026 (ATM facility generated $0 vs. $347,549 in Q1 2025). The ATM facility was refreshed in March 2026 to $1.064 million capacity but remains undrawn. Warrant liability decreased from $703 to $438 QoQ, immaterial to recovery analysis. The going concern opinion from the 2025 annual audit and the going concern disclosure repeated in this 10-Q are explicit. Under strict liquidation analysis: recoverable assets equal cash at 100% ($4.53 million) plus negligible prepaid insurance and interest receivable at a small haircut, against face-value liabilities. The UCLA Diligence Fee ($8.0 million, contingent on first product sale) would not be triggered in a pure wind-down without a licensed product sale, but the obligation survives termination and would attach to any IP asset transfer — constraining any M&A exit value. Net equity recovery to common on a stop-operating basis is modestly positive if the Diligence Fee is not triggered, but the going-concern burn rate creates a closing window. The MFFAIS liquidation values (CLV/LLV/OLV all $10.25 million) appear inconsistent with the $4.53 million cash balance and are not reconcilable from disclosed figures; filing does not separately tag any balance sheet asset or liability amounts in XBRL TAG_CONTEXT.
▼ Community Notes